Table 2 Statin use and CRC risk.
From: Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause
Controls | CRC cases | Adjusted ORb | 95% CI | P-value | ||||
|---|---|---|---|---|---|---|---|---|
Statin users | %a | Statin users | %a | |||||
Statin characteristics | ||||||||
Lipophilicity | Non-users | 2209 | 80.5 | 1086 | 81.3 | 1.00 | ||
Lipophilic | 508 | 18.5 | 223 | 16.7 | 0.79 | 0.66–0.96 | 0.016 | |
Hydrophilic | 26 | 0.9 | 26 | 1.9 | 1.69 | 0.94–3.04 | 0.077 | |
Potency | Non-users | 2209 | 80.5 | 1086 | 81.3 | 1.00 | ||
Low | 346 | 12.6 | 154 | 11.5 | 0.82 | 0.66–1.01 | 0.066 | |
High | 189 | 6.9 | 96 | 7.2 | 0.88 | 0.66–1.16 | 0.38 | |
Subgroup analysis | ||||||||
Gender | Non-users | 1087 | 67.0 | 382 | 60.4 | 1.00 | ||
Female | 188 | 11.6 | 89 | 14.1 | 0.92 | 0.68–1.24 | 0.58 | |
Male | 347 | 21.4 | 161 | 25.4 | 0.80 | 0.64–1.00 | 0.046 | |
Cancer location | Non-users | 2209 | 80.5 | 626 | 73.1 | 1.00 | ||
Colon | 535 | 19.5 | 144 | 16.8 | 0.86 | 0.69–1.06 | 0.16 | |
Rectum | 86 | 10.0 | 0.81 | 0.62–1.06 | 0.13 | |||
